The Centers for Medicare and Medicaid Services appear to be anticipating much stronger near-term uptake of Eisai Co., Ltd. and Biogen, Inc.’s Leqembi (lecanemab-irmb) for Alzheimer's disease than the companies do, based on a forecast recently disclosed by the agency.
Key Takeaways
-
Medicare Part B spending on Leqembi for Alzheimer’s will total $3.5bn in 2025, according to CMS.
CMS expects Medicare Part B spending on Leqembi will reach approximately $3.5bn in 2025 across the fee-for-service and Medicare Advantage...